Study identifier:BY9010/M1-413
ClinicalTrials.gov identifier:NCT00384475
EudraCT identifier:N/A
CTIS identifier:N/A
A randomized, double-blind, placebo-controlled, parallel-group study using the Environmental Exposure Chamber (EEC) to assess the Onset of Action of Ciclesonide, applied as a Nasal Spray (200 mcg, once daily), in the treatment of Seasonal Allergic Rhinitis (SAR) in patients 18 years and older
Rhinitis, Allergic, Seasonal
Phase 3
No
Ciclesonide Nasal Spray
All
500
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2016 by AstraZeneca
AstraZeneca
-
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of seasonal allergic rhinitis caused by pollen. Ciclesonide will be administered once during the exposure to ragweed pollen in a controlled environment. The study duration consists of a baseline period (up to 5 days) and a treatment period (1 day). The study will provide further data on safety and tolerability of ciclesonide.
Location
Location
Ontario, Mississauga, Canada, L4W 1N2
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.